About AVM

About AVM Biotechnology

Founded in 2008, AVM Biotechnology is dedicated to the discovery, development, and commercialization of stem cell-enabling technologies for regenerative medicine, immuno-oncology and fully human biologics applications. Between 2012 and 2017, AVM Biotechnology has successfully raised $10 million from friends and family. With global robust intellectual property (IP) and broad patent claims, AVM’s lead small molecule AVM0703 is ready for Phase 1/2 clinical trials in 2018.

About AVM Founder & Management Member

Theresa Deisher, Ph.D.

Theresa A. Deisher, Ph.D. graduated from Stanford University School of Medicine with a doctoral degree in Molecular & Cellular Physiology. She has over 35 issued US/Japan patents and 3 discoveries in clinical trials. She has had extensive scientific and management experience in the commercial biotechnology field, including:

  • Genentech 1988-1990
  • Repligen 1993-1995 – Hematopoietic Stem Cell Chemoattractants
  • ZymoGenetics 1995-2000 – Adult Cardiac Stem Cell; Mesodermal – Derived Stem Cell; VSEL Very Small Embryonic-Like Stem
  • Immunex/Amgen 2000-2006 – Derivation of Embryonic-Like Stem Cells from Human Cord Blood.